Inclusion Criteria:

• 18 years of age or older, either gender and any race
• OAG or OHT
• Not currently on any IOP-lowering medication or currently on a stable treatment (i.e, at least 30 days) with and IOP-lowering monotherapy.

• All patients: Mean IOP in same eye (at both Eligibility 1 & 2 Visits)

  • 24 and ≤ 36 mmHg at 9 AM
  • 21 and ≤ 36 mmHg at 11 AM & 4 PM

Exclusion Criteria:

• Females of childbearing potential not meeting conditions set in the protocol.
• Severe central visual field loss
• Angle Shaffer grade < 2
• Cup/disc ratio > 0.8 (horizontal or vertical measurement)
• Best corrected VA score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal)
• Intraocular surgery or trauma within last 6 months
• Any abnormality preventing reliable applanation tonometry
• History of or current ocular pathology (including severe dry eye) that would affect the conduct of the study
• Allergy/hypersensitivity to study medications
• Unable to discontinue use of IOP-lowering medication for a minimum wash-out period of 5 to 28 days prior to the Eligibility Visit
• Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP.
• Use of any additional topical or systemic ocular hypotensive medication during the study.
• Therapy with another investigational agent within 30 days prior to the Screening visit.